Showing results (1981-1990 of 2,088) with videos related to

Sort By:
Pageof 209
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
Endocrinology|May 8, 2021
A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer MetastasisRebecca J Watters, Kostas Verdelis, Peter C Lucas, et al.
Journal of Vascular and Interventional Radiology : JVIR|April 11, 2021
Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical TranslationSamdeep K Mouli, Simone Raiter, Kathleen Harris, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2019
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trialsSheri L Spunt, Nadine Francotte, Gian Luca De Salvo, et al.
NPJ Breast Cancer|July 3, 2019
FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtypeKevin M Levine, Nolan Priedigkeit, Ahmed Basudan, et al.
Frontiers in Immunology|August 8, 2014
Next generation sequencing reveals skewing of the T and B cell receptor repertoires in patients with wiskott-Aldrich syndromeAmy E O'Connell, Stefano Volpi, Kerry Dobbs, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2020
SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytesYize Li, David M Renner, Courtney E Comar, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 24, 2001
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemiaM H Davidson, E A Stein, D B Hunninghake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 24, 2023
Stable Decoding from a Speech BCI Enables Control for an Individual with ALS without Recalibration for 3 MonthsShiyu Luo, Miguel Angrick, Christopher Coogan, et al.
Pageof 209